Company Profile

Rock Immune is structured around developing and commercialization of diphtheria toxin based recombinant immunotoxins as therapeutic drugs for treatment of cancer and autoimmune diseases. The company’s immediate objectives are to complete the IND-enabling studies of the CCR4-IL2 bispecific immunotoxin (CCR4-IL2 IT) and demonstrate early clinical phase efficacy in the treatment of refractory/recurrent CTCL. The longer-term vision is to grow the firm to become a leading diphtheria toxin-based immunotoxin drug discovery and development company. CCR4-IL2 IT is genetically engineered to contain both anti-human CCR4 scFv and human IL2 fused to a truncated diphtheria toxin. CCR4-IL2 IT has demonstrated promising preclinical efficacy in a mouse tumor model showing 106% improvement in survival (69 vs. 33.5 days) compared to an IL-2 fusion toxin (Ontak-like). CCR4-IL2 IT also has the potential to deplete tumor infiltrating CCR4+ and/or CD25+ Tregs to improve tumor immunity. CCR4-IL2 IT is part of Spark project